Evidence map›Paper›PMID 35450456›Full record

Trial reportEuropean journal of ophthalmology2023

Sodium hyaluronate 0.30% ocular gel versus sodium hyaluronate 0.18% eye drop in the treatment of moderate to severe dry eye disease.

Margarita Calonge, Marwan Sahyoun, Stéphanie Baillif, Philippe Gain, Ewa Paw, Ali Mearza, Béatrice Cochener

Open access · greenAbstract readComparative StudyEquivalence TrialMulticenter Study
In one paragraph

Trial report in European journal of ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Margarita Calonge537068IOBA (Institute of Applied Ophthalmobiology), University of Valladolid, Valladolid, Spain.
Marwan SahyounHorus Pharma, Saint-Laurent-du-Var, France.ORCID 0000-0002-5012-9473
Stéphanie BaillifPasteur 2 University Hospital, 37045Côte d'Azur University, Nice, France.ORCID 0000-0003-1700-8570
Philippe GainCHU de Saint-Etienne, Saint-Priest-en-Jarez, France.
Ewa PawEurofins Dermscan Poland Sp. z o. o., Gdańsk, Poland.
Ali Mearza8946Imperial College Healthcare NHS Trust, London, UK.
Béatrice CochenerDepartment of Ophthalmology, University Hospital Morvan, Brest, France.
Centre Hospitalier Régional Universitaire de Brest · FRHôpital Pasteur · FRImperial College Healthcare NHS Trust · GBInstitute Cancer De La Loire Lucien Neuwirth · FRUniversidad de Valladolid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCompare 0.30% sodium hyaluronate (0.30%HA) ocular gel with 0.18%HA eye drops in terms of improvement of ocular signs and symptoms, in patients with moderate to severe dry eye disease (DED).

methodsThis was a multicentric, randomized, investigator-masked, non-inferiority, comparative study conducted over 84 days. Three visits were scheduled, testing fluorescein corneal and conjunctival staining (Oxford and Van Bijsterveld scores), tear film break-up time (TBUT), Schirmer test, DED symptoms, 5-Item-Dry-Eye-Questionnaire (5-DEQ), patient and investigator satisfaction and frequency of instillation.

resultsAt Day 35 (D35) and Day 84 (D84), both groups (n = 35 each) had a significant improvement in corneal staining (p < 0.001) with no inter-group difference. Van Bijsterveld score improved earlier (D35) for 0.30%HA suggesting a faster effect on conjunctival epithelium healing. There was no difference between the two concentrations in terms of TBUT or Schirmer improvements; however, the Schirmer test increase was only significant for 0.30%HA at D35 (p = 0.040). At D35 and D84, both groups showed similar improvements of DED symptoms and DEQ-5 score. Furthermore, treatment satisfaction was similar for the 2 formulations suggesting that daily use of 0.30%HA do not cause gel-related blurred vision disturbances. Frequency of instillation was similar for both groups.

conclusionOur study demonstrates the non-inferiority of 0.30%HA gel compared to 0.18%HA solution in patients with moderate to severe DED. Because of its gel formulation and higher HA concentration providing prolonged comfort without causing visual disturbances, 0.30%HA gel might be adapted for bedtime use or during the day in more severe conditions.

Indexed as

Dry Eye SyndromesHyaluronic AcidConjunctivaFluoresceinHumansOphthalmic SolutionsTearsFluoresceinHyaluronic AcidOphthalmic Solutions0.18%0.30%dry eye diseaseefficacyhyaluronic acidOcular gelsodium hyaluronate

Identifiers

PMID35450456
PMCPMC9834324
OpenAlexW4224240513

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.